As the CPG world knows, this shift is bigger than GLP-1
Emerging research suggests that GLP-1RAs may also be beneficial in treating conditions like obstructive sleep apnea (Malhotra et al., 2024), osteoarthritis (Bliddal et al., 2024), metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis with liver fibrosis (MASH) (Loomba et al., 2024), polycystic ovary syndrome (PCOS) (Szczesnowicz et al., 2023), Alzheimers disease (Liang et al., 2024), Parkinsons disease (Kalinderi et al., 2024), and addiction (Klausen et al., 2022)
Bone function, dysfunction and its role in diseases including critical illness
Muhammad Khalid MBBS FCPS (Urology) MCPS (Gen
Mortality outcomes in HFpEF remain a critical area of unmet need, and the potential of SGLT2Is to address this gap, particularly in complex patient populations with overlapping cardiovascular and metabolic risks, warrants further exploration